AC Immune S.A.
ACIU · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -28.1% | 31.9% | -12.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,652.6% | -1,570.9% | -1,854.8% | -1,339.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,688.8% | -1,622.4% | -1,922.1% | -1,389.4% |
| EPS Diluted | -0.16 | -0.21 | -0.19 | -0.15 |
| % Growth | 23.8% | -10.5% | -26.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |